Image: Pille-Riin Priske Avacta has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high throughput COVID-19 bead-assisted mass spectrometry (BAMS) laboratory assay developed with Adeptrix. The COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR), recently funded by the National Institute for Health… Read More
Share Share Tweet Email Could marine alga be a remedy against infections and skin cancer? Could marine alga be a remedy against infections and skin cancer? 6 July 2020 Image: Shane Stagner Marine organisms… Read More
Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More
By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for high quality… Read More
Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 - Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role in disease… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace the expectations of ’omicsbased… Read More
The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More
The Data Driven Transformation In Drug Discovery Dr Satnam Surae This article, presents a review of the current approaches to data management and application within the drug development and research setting, highlighting major critical challenges and emerging solutions for organisations that are determined to harness big data and machine learning. Read More
The Mass Spectrometry Innovations Simplifying Drug Discovery Workflows Helen Stewart-Miller and Dr Richard Massey Mass spectrometry (MS) has long been a valuable tool for drug discovery, and steady advances in its capabilities and performance have generated powerful insights for the pharmaceutical industry. The latest mass spectrometry innovations are now helping… Read More
Microfluidics - Driving Innovation and Streamlining Single Cell Analysis By Dr Frank F. Craig Microfluidics platforms that harness picodroplet technology (picolitre volume aqueous droplets in stabilised oil emulsions) are unlocking the potential of single cell analysis to enable exciting new discoveries and advances with the potential to transform scientific research,… Read More
Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More
Kinases - Shedding Light on Kinase Drug Discovery By Dr Gary Allenby This article discusses the application of new assay technologies to shed light on kinase drug discovery. The human kinome comprises 518 known protein kinases and more than 20 lipid kinases. Nearly all aspects of control within a cell… Read More
Technology Innovation Will Help Prepare Drug Discovery for Smart Screening Era By Dr Clive Green and Dr Philip Spencer Drug discovery is undergoing a transformation powered by advances that magnitude more molecules and enable smarter selection of compounds. We are on the cusp of having previously unimaginable amounts of information… Read More
Novel Drug Targets From Phenotypic Screening By Dr Jim Freeth, Dr Elizabeth Kingsley & Jo Soden Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug… Read More
Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More